Um die volle Funktionalität der Webseite nutzen zu können, müssen Sie JavaScript in ihrem Browser aktivieren.

DAX24.167,59+0,51 %

Gold3.330,43+0,23 %

Öl (Brent)68,25-0,81 %

Dow Jones44.164,26+0,33 %

US Tech 10022.844,15-0,17 %

EUR/USD1,15805-0,17 %

Top 15 der gesamten Suchanfragen der letzten 7 Tage

Login

Biodexa Pharmaceuticals Aktie

Aktie

ISIN: US59564R8079 WKN: A40QEZ SYM: BDRX Land Flagge GB

Großbritannien

Zur Watchlist hinzufügen Zum Portfolio hinzufügen

Zum Portfolio hinzufügen

0,8799

USD

-12,01 %

-0,1201 USD

Letzter Kurs 02:00:00 NYSE

Biodexa Pharmaceuticals Aktie kaufen

Geldkurs

15.07.25

0,8698

USD

100 STK

Briefkurs

15.07.25

0,8887

USD

100 STK

BEI SMARTBROKER+ HANDELN

Hinweis
Verlängerte Handelszeiten
Ab sofort von 07:30 bis 23:00 Uhr

Baader Tragding

Neueste Nachrichten

Biodexa Hits Key Milestone For Its Type 1 Diabetes Candidate Tolimidone, Enrolls First Patient In Phase 2a Study 18.06.25 · Accesswire · Biodexa Pharmaceuticals
With Fast Track Designation in Hand, a Successful Protocol Discussion with FDA, and CROs in Place, Biodexa is on Track to Initiate its Funded Phase 3 Trial in FAP Next Quarter 19.03.25 · Accesswire · Biodexa Pharmaceuticals
Following Positive Phase 2 Results and Orphan Drug Designation, Biodexa's FAP Drug Receives FDA Fast Track Status 12.02.25 · Accesswire · Biodexa Pharmaceuticals
Gaining Momentum, Biodexa is Advancing Two Recent Acquisitions Through the Clinic 21.11.24 · Accesswire · Biodexa Pharmaceuticals
BDRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation Into Biodexa Pharmaceuticals Plc and Encourages Investors to Contact the Firm 28.10.24 · Business Wire (engl.) · Biodexa Pharmaceuticals
BDRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation Into Biodexa Pharmaceuticals Plc and Encourages Investors to Contact the Firm 20.10.24 · Business Wire (engl.) · Biodexa Pharmaceuticals
Biodexa's MX-110 Continues to Show Promise in Recurrent Glioblastoma (rGBM), the Deadliest Brain Cancer 17.10.24 · Accesswire · Biodexa Pharmaceuticals

Meistgelesen

30 Tage
12 Monate

Biodexa Hits Key Milestone For Its Type 1 Diabetes Candidate Tolimidone, Enrolls First Patient In ... 112 Leser

BDRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation Into Biodexa Pharmaceuticals Plc ... 132 Leser
BDRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation Into Biodexa Pharmaceuticals Plc ... 128 Leser
Biodexa Hits Key Milestone For Its Type 1 Diabetes Candidate Tolimidone, Enrolls First Patient In ... 112 Leser
With Fast Track Designation in Hand, a Successful Protocol Discussion with FDA, and CROs in Place, ... 112 Leser
Gaining Momentum, Biodexa is Advancing Two Recent Acquisitions Through the Clinic 112 Leser
Biodexa's MX-110 Continues to Show Promise in Recurrent Glioblastoma (rGBM), the Deadliest Brain ... 108 Leser
Following Positive Phase 2 Results and Orphan Drug Designation, Biodexa's FAP Drug Receives FDA ... 104 Leser